ABSTRACT Statistical analysis and Monte Carlo simulation were used to characterize uncertainty in the allometric exponent (b) of xenobiotic clearance (CL). CL values for 115 xenobiotics were from published studies in which at least 3 species were used for the purpose of interspecies comparison of pharmacokinetics. The b value for each xenobiotic was calculated along with its confidence interval (CI). For 24 xenobiotics (21%), there was no correlation between log CL and log body weight. 
INTRODUCTION
Biological structures and processes ranging from cellular metabolism to population dynamics are affected by the size of the organism 1, 2 . Although the sizes of mammalian species span 7 orders of magnitude, interspecies similarities in structural, physiological, and biochemical attributes result in an empirical power law (the allometric equation) that characterizes the dependency of biological variables on body mass:
where Y is the dependent biological variable of interest, a is a normalization constant known as the allometric coefficient, BW is the body weight, and b is the allometric exponent. The exponential form can be transformed into a linear function:
Log Y = Log a + b (Log BW), and a and b can be estimated from the intercept and slope of a linear regression analysis. The magnitude of b characterizes the rate of change of a biological variable subjected to a change of body mass and reflects the geometric and dynamic constraints of the body 3, 4 .
Although allometric scaling of physiological parameters has been a century-long endeavor, no consensus has been reached as to whether a universal scaling exponent exists. In particular, discussion has centered on whether the basal metabolic rate scales as the 2/3 or 3/4 power of the body mass 1,2,3-9 .
Allometric scaling has been applied in pharmacokinetics for approximately 2 decades. The major interest has been prediction of pharmacokinetic parameters in man from parameter values determined in animals [10] [11] [12] [13] [14] [15] . Clearance has been the most studied parameter, as it determines the drug-dosing rate. In most cases, the pharmacokinetics of a new drug was studied in several animal species, and the allometric relationship between pharmacokinetic parameters and body weight was determined using linear regression of the log-transformed data. One or more of the following observations apply to most such studies: (i) Little attention was given to uncertainty in the a and b values; although the correlation coefficient was frequently reported, the confidence intervals of the a and b values were infrequently addressed.
(ii) The a and b values were used for interspecies extrapolation of pharmacokinetics without analysis of the uncertainty in the predicted parameter values. (iii) The b value of clearance was compared with either the value 2/3 from "surface law" or 3/4 from "Kleiber's law" and the allometric scaling of basal metabolic rate. This paper addresses the possible impact of the uncertainty in allometric scaling parameters on predicted pharmacokinetic parameter values. We combined a statistical analysis of the allometric exponent of clearance f rom 115 xenobiotics and a Monte Carlo simulation to characterize the uncertainty in the allometric exponent for clearance and to investigate whether a universal exponent may exist for the scaling of xenobiotic clearance.
MATERIALS AND METHODS

Data collection and statistical analysis
Clearance (CL) and BW data for 115 substances were collected from published studies in which at least 3 animal species were used for the purpose of interspecies comparison of pharmacokinetics . A total of 18 species (16 mammals, 2 birds) with body weights spanning 10 4 were involved ( Table  1) . Previously published studies generally did not control or standardize across species the (i) dosage, (ii) numbers of individuals studied per species, (iii) principal investigator, (iv) blood sampling regime, or (v) gender. Linear regression was performed on the logtransformed data according to the equation, Log CL = log a + b * log BW. Values for a and b were obtained from the intercept and the slope of the regression, along with the coefficient of determination (r 2 ). Statistical inferences about b were performed in the following form:
Where ß = 0, ß 1 = 2/3, and ß 2 = 3/4, respectively. The 95% and 99% confidence intervals (CI) were also calculated for each b value. In addition, the CL values for each individual xenobiotic were normalized so that all compounds had the same a value. Linear regression analysis was applied to the pooled, normalized CL versus BW data for the 91 xenobiotics that showed statistically significant correlation between log CL and log BW in Table 1 .
Monte Carlo simulation
The power function CL = a BW b was used to generate a set of error-free CL versus BW data. The values for BW were 0.02, 0.25, 2.5, 5, 14, and 70 kg, which represented the body weights of mouse, rat, rabbit, monkey, dog, and human, respectively. The values of a and b used in the simulation were 100 and 0.75, respectively. Random error was added to the calculated CL values, assuming a normal distribution of error with either a 20% or a 30% coefficient of variation (CV), using the function RANDOM in Mathematica 4.0. (Wolfram Research, Champaign, IL) The b and r values were obtained by applying linear regression analyses on the log-log-transformed error-containing CL versus BW data using the Mathematica function REGRESS. Ten scenarios with a variety of sampling regimens that covered different numbers of animal species (3-6) with various body weight ranges (varying 5.6-to 3500-fold) were simulated (n = 100 per scenario). The simulations mimicked the sampling patterns commonly adopted in the published interspecies pharmacokinetics studies.
RESULTS
The allometric scaling parameters and their statistics are listed in Table 1 . Of 115 compounds, 24 (21%) showed no correlation between clearance and body weight; in other words, there was a lack of statistical significance for the regression ( P > 0.05). This generally occurred when only 3 species were used. Among the remaining 91 cases, the mean ± standard deviation of the b values was 0.74 ± 0.16 with a wide range from 0.29 to 1.2 ( Figure  1) . The frequency distribution of the b values appeared to be Gaussian. The mean significantly differed from 0.67 (P < 0.001) but not from 0.75. When the b value of each substance was tested statistically against both 0.67 and 0.75, the majority of the cases (81% and 98% at the level of significance equal to 0.05 and 0.01, respectively) failed to reject the null hypotheses raised against both values ( Table 1) Note: CI = confidence interval * Group 1 = protein; group 2 = xenobiotics that were eliminated mainly by renal excretion; group 3 = xenobiotics that were eliminated mainly by extensive metabolism; group 4 = xenobiotics that were eliminated by both renal excretion and nonrenal metabolism Figure 3 shows the relationship between normalized clearances and body weights (n = 460) for the 91 xenobiotics that showed a statistically significant correlation in Table 1 . The regression slope was 0.74, and the 99% CI was 0.71 to 0.76. The normalized clearances were divided into four groups: 9 proteins (Group 1, n = 41), 21 compounds eliminated mainly via renal excretion (Group 2, n = 105), 39 compounds eliminated mainly via extensive metabolism (Group 3, n = 203), and 22 compounds eliminated by both renal excretion and metabolism (Group 4, n = 111) (Figure 3) . The summary of the regression results appears in Table 3 . While Groups 1, 3, and 4 had b values close to 0.75 and significantly different from 0.67 (P < 0.001), Group 2 had a b value close to 0.67 and significantly different from 0.75 (P < 0.001).
DISCUSSION
Successful prediction of human clearance values using allometric scaling and clearance values measured in animals depends heavily on the accuracy of the b value. Retrospective analysis of published results for 115 substances indicated that the commonly used experimental designs result in considerable uncertainty for this parameter ( Table  1) .
CL values for 24 of the substances listed in Table 1 failed to follow the allometric equation at the 95% confidence level. The failures appeared to result from the following factors: (i) Only 3 species were studied in 16 cases, which severely limited the robustness of the statistics. In the remaining 8 failed cases, 1 or more of the following occurred: (ii) The species were studied in different labs in 3 cases, (iii) small (n = 2) or unequal (n = 2-10) numbers of animals per species were studied in 4 cases, (iv) different dosages among species were used in 2 cases, and (v) high interspecies variability in UDPglucuronosyltransferase activity was proposed in 1 case 75 . The failure of these 24 cases to follow the allometric equation appeared for the most part, therefore, to result from deficiencies in experimental design-in other words, failure of detection rather than failure of the particular substance's CL to follow the allometric relationship. How well did allometry applied to animal CL values predict the human CL value? One ind ication is how close the human CL value fell to the fitted line. Of the 91 substances that followed the allometric equation, 68 included human as 1 of the species. In 41 cases, the human CL value fell below the line, and in 27 cases it fell above (Figure 4) . The mean deviation was only 0.62%, and the majority of deviations were less than 50%. It therefore appeared that for most of the 68 substances studied with human as one of the species, the human CL value did not deviate systematically or extraordinarily from the fitted allometric equation. The tendency, noted by others 10, 12 , of the CL value for human to be lower than that predicted from animal CL values was therefore not apparent in this large data set. The b values for the 91 substances that followed the allometric equation appeared to be normally distributed around a mean value of 0.74, but the range of values was quite broad (Figure 1) . Although impossible to answer definitively with these data, the question of whether there is a "universal" b value is of interest. Does the distribution shown in Figure 1 both mammalian glomerular filtration rate and effective renal plasma flow [91] [92] [93] , although it was consistent with a b value of 0.66 reported for intraspecies scaling of inulin-based glomerular filtration rate in humans 94 and with a b value of 0.69 for scaling creatinine clearance 95 .
Whether the metabolic rate scales to the 2/3 or the 3/4 power of body weight has been the subject of debate for many years. No consensus has been reached. The surface law that suggested a proportional relationship between the metabolic rate and the body surface area was first conceptualized in the 19th century. It has gained support from empirical data 6, 96 as well as statistical 6, 9 and theoretical 6, 97 results. In 1932, Kleiber's empirical analysis led to the 3/4-power law, which has recently been generalized as the quarter-power law by West et al. 3, 4 . Different theoretical analyses based on nutrient-supply networks 3, 8 and 4-dimensional biology 4 all suggested that the quarter-power law is the universal scaling law in biology 98 . However, the claim of universality was challenged by Dodds et al. 9 , whose statistical and theoretical reanalyses cannot exclude 0.67 as the scaling exponent of the basal metabolic rate.
The logic behind the pursuit of a universal law for the scaling of energy metabolism across animal species is mainly based on the assumption that an optimal design of structure and function operates across animal species 3, 4, 8, [99] [100] [101] . Given the fact that all mammals use the same energy source (oxygen) and energy transport systems (cardiovascular, pulmonary) and given the possibility that evolutionary force may result in a design principle that optimizes energy metabolism systems across species, the existence of such a law might be possible. However, available data and analyses have not led to a conclusion.
A large body of literature data has indicated that the allometric scaling relationship applies to the clearance of a variety of xenobiotics. It has been speculated that xenobiotic clearance is related to metabolic rate, and clearance b values have frequently been compared with either 0.67 or 0.75. The b values obtained from the scaling of clearance for a variety of xenobiotics tended to be scattered. Our analysis indicated that the b value generally fell within a broad range between 0 and 1 or even higher. The scatter of b values may have resulted from the uncertainty that accrued from the regression analysis of a limited number of data points as discussed above. In addition, the scatter may have involved the variability in pharmacokinetic properties among different xenobiotics. This variability rendered the prediction of the b value extremely difficult. Moreover, the discussio n of "universality" of the b value was less possible in this regard. From the pharmacokinetics point of view, lack of a unique b value for all drugs may be considered as a norm. In this regard, the uncertainty and variability became a universal phenomenon. To determine whether a unique b value exists for the scaling of CL, a more rigorous experimental design has to be included to control the uncertainty that may obscure the conclusion. Although a study that includes the CL data for a variety of drugs covering the animal species with a scope similar to that of its counterpart in scaling basal metabolic rate might be sufficient, it would also be extremely unrealistic. Therefore, from the perspective of pharmacokinetics where the drug is the center of discussio n, it is almost impossible to address whether the b value of CL tended to be dominated by 1 or 2 values. However, from the perspective of physiology where the function of a body is of interest, systematic analysis of currently available data in interspecies scaling of CL may provide some insight into the interspecies scaling of energy metabolism. The rationale behind this line of reasoning was that the elimination of a xenobiotic from a body is a manifestation of physiological processes such as blood flow and oxygen consumption. Interestingly, the two competitive exponent values, but not others, in theorizing the scaling of energy metabolism reappeared in our analysis. The value 0.75 appeared to be the central tendency of the b values for the CL of most compounds, except for that of drugs whose elimination was mainly via kidney.
CONCLUSION
Whether allometric scaling could be used for the prediction of the first-time-in-man dose has been debated 102, 103 . Figure 4 shows that a reasonable error range can be achieved when human CL is predicted by the animal data for some drugs.
However, the success shown in the retrospective analysis does not necessarily warrant success in prospective applications. As indicated by our analyses on the uncertainty of b values and as illustrated in Bonate and Howard's commentary 102 , caution is needed when allometric scaling is applied in a prospective manner. In addition, the use of a deterministic equation in predicting individual CL data may be questionable because the intersubject variability cannot be accounted for. Nevertheless, allometric scaling could be an alternative tool, if the mean CL for a population is to be estimated and if the uncertainty is adequately addressed. When the uncertainty in the determination of a b value is relatively large, a fixed-exponent approach might be feasible. In this regard, 0.75 might be used for substances that are eliminated mainly by metabolism or by metabolism and excretion combined, whereas 0.67 might apply for drugs that are eliminated mainly by renal excretion. 
